The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients, as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth, the report states. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future. Further key findings from the study suggest:
- Oral segment dominated the market in 2015
- The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
- Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
- North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
- Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
- Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.
The full report can be viewed
here
.